Mechelen, Belgium; 28 August 2019; 22.01 CEST; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Gilead Sciences, Inc.
Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 28 August 2019
from Gilead Sciences, Inc. (acting as a parent undertaking or a controlling person), who notified that Gilead Therapeutics A1 Unlimited Company, an indirect subsidiary of Gilead Sciences, holds 13,589,686 of Galapagos' voting rights, consisting of 13,589,686 ordinary shares, as a result of subscribing to a capital increase and thus receiving 6,828,985 new Galapagos shares on 23 August 2019. This represents 22.04% of Galapagos' currently outstanding 61,652,086 shares. Gilead Therapeutics A1 Unlimited Company thus crossed above the 20% threshold of Galapagos' voting rights by acquisition of voting securities on 23 August 2019.
The notification specifies furthermore that (i) Gilead Therapeutics A1 Unlimited Company is a direct subsidiary of Gilead Biopharmaceutics Ireland UC, (ii) Gilead Biopharmaceutics Ireland UC is a direct subsidiary of Gilead Sciences, Inc., and (iii) Gilead Sciences, Inc. has no controlling shareholder.
The full transparency notification is available on the Galapagos website.
About Galapagos
Galapagos.
| Galapagos Contacts | |
| Investors: | Media: |
| Elizabeth Goodwin | Carmen Vroonen |
| VP IR | Senior Director Communications |
| +1 781 460 1784 | +32 473 824 874 |
| Sofie Van Gijsel | Evelyn Fox |
| Director IR | Director Communications |
| +32 485 19 14 15 | +31 6 53 591 999 |
| ir@glpg.com | communications@glpg.com |
1 Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
Attachment
- Transparency Notification PR EN (https://ml-eu.globenewswire.com/Resource/Download/5f784d88-d2c2-4553-9228-a6c949431cf3)
